Last updated: October 13, 2026
Revuforj is Syndax Pharmaceuticals' oral menin inhibitor for relapsed or refractory acute leukemia with a KMT2A translocation. The FDA granted accelerated approval on Nov. 15, 2024, making Revuforj the first approved menin-pathway therapy in this setting.[1] Its commercial opportunity is concentrated but strategically important: the eligible population is small, treatment is specialist-driven, and the product addresses a high-mortality molecular subgroup with limited approved alternatives.
The financial trajectory depends on three variables: rapid identification of KMT2A-positive patients, conversion of clinical-trial use into routine treatment, and expansion into frontline or broader acute myeloid leukemia populations. In 2024, Revuforj had no meaningful commercial revenue base because approval occurred late in the year. The primary commercial buildout is therefore a 2025-and-beyond event.
What is Revuforj and what FDA indication does it have?
Revuforj is revumenib, an oral small-molecule inhibitor of the menin-KMT2A interaction. The FDA-approved indication covers adults and pediatric patients age 1 year and older with relapsed or refractory acute leukemia and a lysine methyltransferase 2A gene translocation, commonly called KMT2A-rearranged leukemia.[1]
| Attribute |
Revuforj |
| Active ingredient |
Revumenib |
| Developer |
Syndax Pharmaceuticals |
| Drug class |
Menin inhibitor |
| FDA approval |
Nov. 15, 2024 |
| Approval pathway |
Accelerated approval |
| Disease setting |
Relapsed or refractory acute leukemia |
| Biomarker |
KMT2A translocation |
| Dosage form |
Oral tablets and oral capsules |
| Patient population |
Adults and pediatric patients age 1 year and older |
| Regulatory basis |
Response rate and duration of response in a single-arm study |
| Key confirmatory obligation |
Randomized confirmatory development in earlier-line disease |
The approval was based principally on the AUGMENT-101 study, which enrolled patients with relapsed or refractory acute leukemia carrying a KMT2A rearrangement. The FDA label identifies differentiation syndrome, QTc prolongation, and embryofetal toxicity among the principal safety risks.[1]
How large is the Revuforj commercial market?
The initial market is an orphan oncology market rather than a broad acute myeloid leukemia market. KMT2A rearrangements occur in a minority of acute leukemias, with a higher incidence in infant and pediatric acute lymphoblastic leukemia and a clinically important presence in adult acute myeloid leukemia.
Commercial demand is supported by four factors:
- KMT2A-rearranged disease has poor outcomes after relapse.
- The biomarker is identifiable through cytogenetic and molecular testing.
- There was no previously approved targeted menin inhibitor in the United States.
- Treatment is used in a setting where physicians have limited durable options.
The market is constrained by the narrow label, low prevalence, competing salvage regimens, transplantation pathways, and the need to confirm the diagnosis before prescribing.
Patient flow and treatment economics
The commercial funnel is likely to run through academic leukemia centers, transplant hospitals, pediatric oncology networks, and specialty pharmacies. The highest-value patients are those who:
- Have confirmed KMT2A rearrangement;
- Have relapsed or refractory disease;
- Are medically fit for oral therapy;
- Have a treatment objective that includes remission or bridge to transplantation.
Revuforj can generate revenue through repeated treatment cycles, but treatment duration will vary by response, toxicity, transplantation, and disease progression. The product's economic value is higher when it produces a remission that enables allogeneic stem-cell transplantation.
What is the Revuforj pricing and reimbursement outlook?
Syndax launched Revuforj as a specialty oncology product with pricing intended for a rare, high-acuity population. The relevant commercial metrics are gross-to-net-adjusted sales, treatment duration, payer approval rates, and the percentage of patients treated through commercial insurance, Medicare, Medicaid, or manufacturer assistance programs.
Reimbursement risk is moderate rather than negligible. Payers generally recognize FDA-approved oncology drugs, but the accelerated-approval status, high treatment cost, pediatric use, and biomarker-confirmation requirement can create prior-authorization friction.
The key market-access requirements include:
- Documentation of KMT2A rearrangement;
- Confirmation of relapsed or refractory disease;
- Appropriate dosing by age and concomitant medications;
- Monitoring for differentiation syndrome and QTc effects;
- Coordination with a specialty pharmacy or oncology distributor.
What is the financial trajectory for Revuforj and Syndax?
Revuforj's financial profile has three phases.
Phase one: launch investment
The first phase includes sales-force deployment, medical-affairs hiring, payer contracting, diagnostic education, patient-support programs, inventory creation, and post-approval studies. These costs can depress operating margins before revenue reaches scale.
Syndax's commercial strategy is likely to prioritize high-volume leukemia centers rather than broad community-oncology coverage. That approach limits selling expense relative to a mass-market oncology launch but requires intensive physician education and molecular-testing support.
Phase two: orphan-market penetration
The second phase depends on the speed at which physicians adopt Revuforj after failure of existing salvage therapy. Early revenue is likely to be concentrated among:
- Academic medical centers;
- Patients previously enrolled in AUGMENT-101;
- Adults with relapsed acute myeloid leukemia;
- Pediatric and young-adult leukemia programs;
- Patients being evaluated for transplantation.
Revenue growth can be rapid from a small base if diagnosis and access barriers are managed. The main limitation is the number of newly diagnosed eligible patients, not general awareness of the drug.
Phase three: label expansion
The largest financial upside requires use in earlier-line disease or combinations. Syndax's development strategy has focused on moving menin inhibition into broader treatment settings, including combinations with established acute leukemia regimens.[2] A successful frontline or consolidation indication would expand the addressable population and increase treatment duration.
The commercial value of Revuforj is therefore asymmetric:
| Scenario |
Commercial effect |
| Narrow relapsed/refractory label only |
Specialist orphan product with controlled but limited revenue |
| Durable responses with bridge to transplant |
Higher treatment persistence and stronger physician adoption |
| Positive confirmatory study |
Reduced regulatory risk and broader payer confidence |
| Frontline approval |
Material expansion of eligible patients |
| Combination-label expansion |
Greater use across treatment lines and higher annual revenue per patient |
| Confirmatory failure |
Risk to approval status, adoption, and valuation |
Syndax's revenue trajectory should be assessed against product sales, cash burn, research-and-development spending, and the need for additional financing. Early product revenue does not automatically translate into profitability because post-approval studies and commercial infrastructure remain costly.
What patents protect Revuforj?
Revuforj's exclusivity position is based on a combination of patent rights, regulatory exclusivity, orphan-drug protections, and pending patent applications. The relevant patent categories include:
- Revumenib composition-of-matter patents;
- Crystal form and salt patents;
- Pharmaceutical composition patents;
- Oral dosage-form patents;
- Methods of treating KMT2A-rearranged leukemia;
- Combination-treatment patents;
- Manufacturing and process patents.
The commercial importance of each category differs. Composition-of-matter rights generally provide the strongest protection. Method-of-use patents can protect particular biomarker-defined populations but may be more vulnerable to non-infringement arguments if a generic omits or disputes the patented indication. Formulation and process patents can complicate generic development but rarely replace a strong composition patent.
A definitive patent-expiration analysis requires the current FDA Orange Book listing, USPTO patent-term data, terminal disclaimers, patent-term adjustments, and any applicable pediatric extensions. The public FDA approval materials establish the regulatory protection framework but do not by themselves establish the complete enforceable patent term.[1]
When does Revuforj lose regulatory exclusivity?
Revuforj received orphan-drug designation for the approved disease setting. Orphan-drug exclusivity generally prevents FDA approval of the same drug for the same indication for seven years from approval, subject to statutory exceptions.[3]
The approval also carries accelerated-approval obligations. The duration of market protection will depend on:
- The seven-year orphan exclusivity period;
- Listed patents and their effective expiration dates;
- Any six-month pediatric exclusivity;
- Patent-term adjustment or extension;
- The outcome of confirmatory trials;
- Potential withdrawal if required clinical benefit is not verified.
Because Revuforj was approved in November 2024, the orphan-exclusivity period would ordinarily extend into November 2031, subject to the legal details of the designation and indication.
What is the Orange Book status of Revuforj?
Revuforj is an FDA-approved small molecule, so its approved product and applicable patents are evaluated through the Hatch-Waxman framework. The Orange Book is the controlling source for listed patents, patent-use codes, and exclusivity information.[4]
Potential future generic challenges could target:
- The active ingredient;
- The listed composition-of-matter patent;
- The dosage form;
- Patent-term calculations;
- Method-of-use claims;
- The scope of the approved indication.
A Paragraph IV certification would create litigation risk if a generic applicant asserts that a listed patent is invalid, unenforceable, or not infringed. The timing of any generic launch would depend on the ANDA filing date, the certification, patent litigation, a 30-month stay, pediatric exclusivity, and the outcome of any settlement.
Which companies are challenging Revuforj?
No approved generic competitor or biosimilar can directly compete with Revuforj at the time of its initial launch. Revumenib is a small molecule, so biosimilar regulation is not applicable.
The most relevant competitive threat is another menin inhibitor, particularly ziftomenib from Kura Oncology. Ziftomenib targets the same general biological pathway and is being developed in KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.[5] Other competition includes:
- Venetoclax-based salvage regimens;
- FLT3 inhibitors for FLT3-mutated disease;
- IDH inhibitors for IDH1- or IDH2-mutated disease;
- Intensive chemotherapy;
- Clinical trials;
- Allogeneic stem-cell transplantation.
Revuforj has a first-mover advantage, but the menin-inhibitor market can become more competitive if a rival obtains an approval in a larger molecular segment such as NPM1-mutated acute myeloid leukemia.
How strong is the Revuforj patent and market position?
Revuforj's market position is strongest in the following areas:
- First approved menin inhibitor;
- Orphan-drug protection;
- High unmet need in KMT2A-rearranged leukemia;
- Specialist prescribing concentration;
- Biomarker-defined patient selection;
- Potential to become a platform for combination therapy.
Its principal weaknesses are:
- Small initial patient population;
- Accelerated-approval obligations;
- Safety monitoring requirements;
- Dependence on molecular testing;
- Potential competition from other menin inhibitors;
- Limited commercial history;
- Exposure to clinical-trial failure in earlier-line disease.
The patent estate is strategically valuable if composition-of-matter protection extends into the late 2030s or beyond. Exact enforceable dates should be determined from the current patent and Orange Book records rather than from approval-date estimates.
What litigation and settlement risks affect Revuforj?
The main near-term legal risk is not a current generic challenge but future Hatch-Waxman litigation. Possible disputes include patent validity, written description, enablement, obviousness, infringement, and the scope of method-of-use claims.
Potential settlement structures could include:
- A licensed generic entry date;
- Authorized-generic supply;
- A covenant not to sue for specific indications;
- Restrictions tied to patent expiration;
- Pediatric exclusivity treatment;
- Different entry dates for different dosage forms.
No broad biosimilar litigation framework applies because Revuforj is not a biologic.
How does Revuforj compare with ziftomenib?
| Factor |
Revuforj |
Ziftomenib |
| Developer |
Syndax Pharmaceuticals |
Kura Oncology |
| Mechanism |
Menin inhibition |
Menin inhibition |
| Lead biomarker |
KMT2A translocation |
KMT2A-rearranged and NPM1-mutated AML development |
| Regulatory position |
First FDA-approved menin inhibitor |
Development-stage competitor at Revuforj approval |
| Initial commercial advantage |
Yes |
No at Revuforj launch |
| Competitive risk |
Narrow label and confirmatory obligations |
Clinical and regulatory execution risk |
| Market expansion |
Earlier-line disease and combinations |
Potentially broader molecular coverage |
The strategic question is whether Revuforj remains a narrowly targeted rescue therapy or becomes the anchor product for menin-based treatment across multiple acute leukemia subtypes.
Key Takeaways
- Revuforj is revumenib, Syndax's first commercial product and the first FDA-approved menin inhibitor.
- FDA approval occurred on Nov. 15, 2024, for relapsed or refractory acute leukemia with a KMT2A translocation.
- The initial market is small, specialized, and biomarker-dependent but has high unmet need.
- Revenue growth depends on uptake at leukemia centers, reimbursement execution, treatment duration, and transplant-bridging use.
- The largest financial upside requires confirmatory success and expansion into frontline or combination therapy.
- Orphan-drug exclusivity would ordinarily provide protection into November 2031, subject to statutory and designation-specific details.
- Generic litigation is a future Hatch-Waxman risk; biosimilar competition is not relevant.
- Ziftomenib is the most important mechanistic competitor because it targets the same menin pathway and may pursue broader acute myeloid leukemia populations.
FAQs About Revuforj Exclusivity, Sales, and Competition
Is Revuforj a biologic or a small-molecule drug?
Revuforj is an oral small-molecule drug. Biosimilar rules do not apply; future generic competition would proceed through the ANDA pathway.
What biomarker is required before prescribing Revuforj?
The patient must have acute leukemia with a KMT2A translocation. Molecular or cytogenetic testing is required to establish eligibility.
Can Revuforj be used before relapse?
The original FDA approval is for relapsed or refractory disease. Earlier-line use would generally require a later approval, a clinical trial, or another legally authorized treatment pathway.
Does Revuforj have orphan-drug exclusivity?
Yes. Revuforj received orphan-drug protection for its rare leukemia indication. The statutory period is generally seven years from approval, subject to applicable exceptions and regulatory conditions.
What is the largest threat to Revuforj revenue?
The largest threats are failure to expand beyond the narrow initial indication, slow molecular testing and reimbursement, confirmatory-trial failure, and competition from another menin inhibitor with broader acute myeloid leukemia coverage.
References
- U.S. Food and Drug Administration. (2024). Revuforj (revumenib) prescribing information and approval announcement. https://www.fda.gov
- Syndax Pharmaceuticals, Inc. (2025). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov
- U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
- Kura Oncology, Inc. (2024). Clinical development information for ziftomenib. https://www.kuraoncology.com